Form 4: CFO Terig Hughes Acquires VNRX Shares via RSU Vesting

VolitionRx CFO Terig Hughes acquired 49,200 shares of common stock through the vesting of restricted stock units, increasing his direct beneficial ownership to 482,970 shares.

Summary

• Terig Hughes, Chief Financial Officer of VolitionRx Ltd (VNRX), acquired 49,200 shares of common stock.
• The acquisition resulted from the vesting of restricted stock units (RSUs) awarded on March 17, 2025, under the Issuer's 2024 Stock Incentive Plan.
• A total of 164,000 RSUs were initially awarded, subject to corporate performance goals and time-based vesting.
• 49,200 RSUs vested due to the achievement of certain corporate performance goals.
• The remaining 114,800 RSUs did not vest and were cancelled on June 30, 2025, and January 22, 2026.
• The 49,200 vested RSUs are subject to a 3-year time-based vesting schedule, with three equal installments of 16,400 units vesting on March 17, 2026, 2027, and 2028.
• Following this transaction, Terig Hughes' direct beneficial ownership of VolitionRx common stock is 482,970 shares.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a significant portion of RSUs did not vest, the vesting of 49,200 units and the resulting increase in insider ownership are generally viewed favorably as they align management's interests with shareholders. The transaction itself is routine for executive compensation.

Positives

• Increased insider ownership: The CFO's direct beneficial ownership increased to 482,970 shares, aligning management interests with shareholders.
• Achievement of performance goals: 49,200 RSUs vested due to the achievement of certain corporate performance goals, indicating some level of operational success.

Negatives

• Partial non-vesting of RSUs: A significant portion of the initially awarded RSUs (114,800 out of 164,000) did not vest due to unmet performance goals, which could suggest some corporate objectives were not fully achieved.

Risks

• Unmet performance goals: The cancellation of 114,800 RSUs due to unachieved corporate performance goals could indicate potential challenges in meeting certain operational or strategic targets.

Future Outlook

The 49,200 vested restricted stock units are subject to a time-based vesting schedule, with shares expected to be received in three equal installments of 16,400 units on March 17, 2026, 2027, and 2028, upon vesting and settlement.

Management Comments

• Terig Hughes, Chief Financial Officer, acquired 49,200 shares of common stock through the vesting of restricted stock units, demonstrating continued participation in the company's equity incentive plan.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the vesting of executive compensation in the form of restricted stock units. Such filings provide transparency into management's equity holdings and alignment with shareholder interests, which is a standard practice across publicly traded companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased insider ownership can be perceived positively, signaling management's confidence and alignment with shareholder interests. However, the partial non-vesting of RSUs might raise questions about the achievement of certain corporate goals.

Next Steps

• Future vesting of 16,400 units on March 17, 2026.
• Future vesting of 16,400 units on March 17, 2027.
• Future vesting of 16,400 units on March 17, 2028.

Key Dates

Recommendation

The filing reports a routine vesting of restricted stock units for a key executive, increasing their direct beneficial ownership. While this demonstrates management's alignment with shareholder interests, it does not represent a discretionary open-market purchase or a significant new strategic development that would warrant a change in investment recommendation. The partial non-vesting of RSUs due to unmet performance goals introduces a minor cautionary note regarding corporate performance, but the overall impact on the company's fundamental outlook is limited.

Keywords

VolitionRx, VNRX, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Chief Financial Officer, Executive Compensation, Beneficial Ownership, Stock Incentive Plan